Finland Biotechnology & Medical Research

Faron Pharmaceuticals Oy (FARN)

Track

Track

Faron Pharmaceuticals Oy experienced notable insider activity on March 1, 2026, when key executives, including the PCA and Non-Executive Chairman, executed significant share purchases. These transactions represent the most recent recorded movements. Prior to this, multiple directors acquired equity in April 2024, reflecting a pattern of leadership investment in the firm.
Ticker: FARN Exchange: LSE
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Faron Pharmaceuticals Oy. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Tuomo Pätsi Non-Executive Chairman Director
Transaction date
Purchase
Price
13.79
Quantity 59,740
Value €1,156,483
Sirpa Jalkanen PCA
Transaction date
Purchase
Price
265.53
Quantity 87,167
Value €1,791,182
Tuomo Pätsi Director Executive Director
Transaction date
Purchase
Price
258.14
Quantity 12,958
Value €3,795,489
Sirpa Jalkanen Director Executive Director
Transaction date
Purchase
Price
1.50
Quantity 79,999
Value €119,998
2.2
Markku Jalkanen Director Executive Director
Transaction date
Purchase
Price
1.50
Quantity 79,999
Value €119,998
John Poulos Non-executive Director Executive Director
Transaction date
Sale
Price
3.83
Quantity 5,000
Value €19,130
John Poulos Non-executive Director Executive Director
Transaction date
Sale
Price
3.72
Quantity 5,000
Value €18,604
2.2
Markku Jalkanen Chief Executive Officer Officer
Transaction date
Purchase
Price
2.82
Quantity 25,000
Value €70,532
2.4
Toni HÄonninen Chief Financial Officer Officer
Transaction date
Purchase
Price
3.51
Quantity 4,400
Value £15,444
2.4
Toni HÄonninen Chief Financial Officer Officer
Transaction date
Purchase
Price
4.33
Quantity 3,500
Value €15,139
1.0
Matti Karvonen VP Drug Development, Chief Medical Officer Officer
Transaction date
Purchase
Price
0.83
Quantity 20,000
Value £16,580
1.4
Minja Pfeiffer Chief Medical Officer Officer
Transaction date
Purchase
Price
1.00
Quantity 4,414
Value £4,414
3.2
Juho Jalkanen Chief Development Officer Officer
Transaction date
Purchase
Price
0.71
Quantity 12,000
Value £8,520
Mehto Saima Kuolinpesä Chief Development Officer Officer
Transaction date
Purchase
Price
0.71
Quantity 24,000
Value £17,040
2.2
Markku Jalkanen Chief Development Officer Officer
Transaction date
Purchase
Price
0.71
Quantity 12,000
Value £8,520
1.4
Minja Pfeiffer Chief Development Officer Officer
Transaction date
Purchase
Price
0.57
Quantity 31,000
Value £17,670
1.0
Matti Karvonen Chief Executive Officer Officer
Through Matti Karvonen, a closely affiliated person
Transaction date
Purchase
Price
0.56
Quantity 15,000
Value £8,400
3.1
Pessi Honkasalo Medical Director Executive Director
Transaction date
Purchase
Price
0.75
Quantity 1,500
Value £1,125
3.3
Yrjö Wichmann Corporate Legal Counsel
Transaction date
Purchase
Price
0.67
Quantity 5,200
Value £3,484
Susanna Hedenström Chief Financial Officer Officer
Transaction date
Purchase
Price
0.56
Quantity 7,900
Value £4,424
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-03-31 2026-03-01 B Purchase
Tuomo Pätsi

Non-Executive Chairman

Director
59,740
13.79
€1,156,483 		59,740 13.79 €1,156,483
2026-03-25 2026-03-01 B Purchase
Sirpa Jalkanen

PCA
87,167
265.53
€1,791,182 		87,167 265.53 €1,791,182
2024-04-04 2024-04-03 B Purchase
Tuomo Pätsi

Director

Executive Director
12,958
258.14
€3,795,489 		12,958 258.14 €3,795,489
2024-04-04 2024-04-03 B Purchase
Sirpa Jalkanen

Director

Executive Director
79,999
1.50
€119,998 		79,999 1.50 €119,998
2024-04-04 2024-04-03 B Purchase
2.2
Markku Jalkanen

Director

Executive Director
79,999
1.50
€119,998 		79,999 1.50 €119,998
2023-10-27 2023-10-12 S Sale
John Poulos

Non-executive Director

Executive Director
5,000
3.83
€19,130 		5,000 3.83 €19,130
2023-10-27 2023-10-03 S Sale
John Poulos

Non-executive Director

Executive Director
5,000
3.72
€18,604 		5,000 3.72 €18,604
2022-04-08 2022-04-05 B Purchase
2.2
Markku Jalkanen

Chief Executive Officer

Officer
25,000
2.82
€70,532 		25,000 2.82 €70,532
2020-07-08 2020-07-08 B Purchase
2.4
Toni HÄonninen

Chief Financial Officer

Officer
4,400
3.51
£15,444 		4,400 3.51 £15,444
2020-05-12 2020-05-12 B Purchase
2.4
Toni HÄonninen

Chief Financial Officer

Officer
3,500
4.33
€15,139 		3,500 4.33 €15,139
2018-11-06 2018-10-26 B Purchase
1.0
Matti Karvonen

VP Drug Development, Chief Medical Officer

Officer
20,000
0.83
£16,580 		20,000 0.83 £16,580
2018-09-18 2018-09-17 B Purchase
1.4
Minja Pfeiffer

Chief Medical Officer

Officer
4,414
1.00
£4,414 		4,414 1.00 £4,414
2018-06-21 2018-06-21 B Purchase
3.2
Juho Jalkanen

Chief Development Officer

Officer
12,000
0.71
£8,520 		12,000 0.71 £8,520
2018-06-21 2018-06-21 B Purchase Mehto Saima Kuolinpesä

Chief Development Officer

Officer
24,000
0.71
£17,040 		24,000 0.71 £17,040
2018-06-21 2018-06-21 B Purchase
2.2
Markku Jalkanen

Chief Development Officer

Officer
12,000
0.71
£8,520 		12,000 0.71 £8,520
2018-06-21 2018-06-21 B Purchase
1.4
Minja Pfeiffer

Chief Development Officer

Officer
31,000
0.57
£17,670 		31,000 0.57 £17,670
2018-06-21 2018-06-21 B Purchase
1.0
Matti Karvonen

Chief Executive Officer

Through Matti Karvonen, a closely affiliated person Officer
15,000
0.56
£8,400 		15,000 0.56 £8,400
2018-06-21 2018-06-21 B Purchase
3.1
Pessi Honkasalo

Medical Director

Executive Director
1,500
0.75
£1,125 		1,500 0.75 £1,125
2018-06-21 2018-06-21 B Purchase
3.3
Yrjö Wichmann

Corporate Legal Counsel
5,200
0.67
£3,484 		5,200 0.67 £3,484
2018-06-21 2018-06-21 B Purchase Susanna Hedenström

Chief Financial Officer

Officer
7,900
0.56
£4,424 		7,900 0.56 £4,424
Explore more

More insider trading research around Faron Pharmaceuticals Oy

More insider trades in Finland
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in Europe